secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-057221
Event type: litigation
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor sues Nippon Shinyaku over failed Deramiocel launch preparations; seeks agreement rescission
--------------------------------------------------------------------------------

- Filing of complaint in NJ Superior Court alleges fundamental pricing flaw in distribution agreement making Deramiocel commercially unviable under Medicare.
- Distributor accused of failing to complete gross-to-net model, mock launch, or obtain required sub-distributor consents for Capricor's cell therapy.
- Pricing structure renders Deramiocel economically impracticable for Medicare, Medicaid, and private insurance patients, per complaint.
- Capricor seeks rescission of distribution agreement, declaratory judgment, and preliminary injunction ahead of PDUFA date of August 22, 2026.
- FDA Priority Review for Deramiocel remains on track; Capricor states it is building commercial readiness independently.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/0001104659-26-057221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer